Clinical Trial Update: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety and efficacy study of lanadelumab for prevention of acute attacks in non-histaminergic angioedema with normal C1-inhibitor has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioedema

Drugs mentioned

• Takhzyro (lanadelumab) (lanadelumab)

Snippet

Sponsor: Shire | Conditions: Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2024-06-17